Survival and Neurologic Recovery After Prompt Diagnosis and Aggressive Management of Severe Idiopathic Hyperammonemic Encephalopathy in a Patient with Acute Myeloid Leukemia.
Journal
Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
pubmed:
16
8
2019
medline:
1
1
2021
entrez:
16
8
2019
Statut:
ppublish
Résumé
A case of a 19-year-old female with low-risk acute myeloid leukemia is presented who was diagnosed with idiopathic hyperammonemic encephalopathy following the development of abrupt neurologic decline, respiratory alkalosis, and elevated plasma ammonia levels of unknown etiology. Delayed symptom recognition of this exceedingly rare condition contributes to the often fatal outcomes of idiopathic hyperammonemic encephalopathy. As illustrated by this case, prompt diagnosis and utilization of a variety of ammonia-modulating treatment modalities can result in remarkable clinical recovery. This case provides guidance to clinicians in counseling families about the possibility of neurologic recovery in similar clinical scenarios.
Identifiants
pubmed: 31415019
doi: 10.1097/MPH.0000000000001579
pii: 00043426-202008000-00020
doi:
Substances chimiques
Phenylbutyrates
0
4-phenylbutyric acid
7WY7YBI87E
Sodium Benzoate
OJ245FE5EU
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e452-e455Références
Gamis AS, Alonzo TA, Meshinchi S, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. J Clin Oncol. 2014;32:3021–3032.
Gossai N, Richards M, Boman L, et al. Symptomatic hyperammonemia with Erwinia chrysanthemi-derived asparaginase in pediatric leukemia patients. J Pediatr Hematol Oncol. 2018;40:312–315.
Nott L, Price TJ, Pittman K, et al. Hyperammonemia encephalopathy: an important cause of neurological deterioration following chemotherapy. Leuk Lymphoma. 2007;48:1702–1711.
Butterworth RF. Pathophysiology of brain dysfunction in hyperammonemic syndromes: the many faces of glutamine. Mol Genet Metab. 2014;113:113–117.
Jaing T-H, Lin J-L, Lin Y-P, et al. Hyperammonemic encephalopathy after induction chemotherapy for acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2009;31:955–956.
Basile AS. Direct and indirect enhancement of GABAergic neurotransmission by ammonia: implications for the pathogenesis of hyperammonemic syndromes. Neurochem Int. 2002;41:115–122.
Norenberg MD, Rama Rao KV, Jayakumar AR. Signaling factors in the mechanism of ammonia neurotoxicity. Metab Brain Dis. 2009;24:103–117.
Rao KV, Norenberg MD. Cerebral energy metabolism in hepatic encephalopathy and hyperammonemia. Metab Brain Dis. 2001;16:67–78.
Valle D, Beaud AL, Vogelstein B, et al. The Online Metabolic and Molecular Bases of Inherited Disease. The McGraw-Hill Companies, Inc.
Takanashi J, Barkovich AJ, Cheng SF, et al. Brain MR imaging in neonatal hyperammonemic encephalopathy resulting from proximal urea cycle disorders. AJNR Am J Neuroradiol. 2003;24:1184–1187.
Neilson DAdam MP, Ardinger HH, Pagon RA, Wallace SE. Susceptibility to infection-induced acute encephalopathy 3. GeneReviews®. Seattle (WA): University of Washington, Seattle; 1993.
Brusilow SW. Hyperammonemic encephalopathy. Medicine (Baltimore). 2002;81:240–249.
Kaufman JJ. Ammoniagenic coma following ureterosigmoidostomy. J Urol. 1984;131:743–745.
Bharat A, Cunningham SA, Scott Budinger GR, et al. Disseminated ureaplasma infection as a cause of fatal hyperammonemia in humans. Sci Transl Med. 2015;7:284re3.
Mitchell RB, Wagner JE, Karp JE, et al. Syndrome of idiopathic hyperammonemia after high-dose chemotherapy: review of nine cases. Am J Med. 1988;85:662–667.
Davies SM, Szabo E, Wagner JE, et al. Idiopathic hyperammonemia: a frequently lethal complication of bone marrow transplantation. Bone Marrow Transplant. 1996;17:1119–1125.
Rose CF. Ammonia-lowering strategies for the treatment of hepatic encephalopathy. Clin Pharmacol Ther. 2012;92:321–331.
Metzeler KH, Boeck S, Christ B, et al. Idiopathic hyperammonemia (IHA) after dose-dense induction chemotherapy for acute myeloid leukemia: case report and review of the literature. Leuk Res. 2009;33:e69–e72.
Upadhyay R, Bleck TP, Busl KM. Hyperammonemia: what urea-lly need to know: case report of severe noncirrhotic hyperammonemic encephalopathy and review of the literature. Case Rep Med. 2016;2016:8512721.
Jover-Cobos M, Khetan V, Jalan R. Treatment of hyperammonemia in liver failure. Curr Opin Clin Nutr Metab Care. 2014;17:105–110.